ClinicalTrials.gg
CompletedNCT06963424Updated Jan 9, 2026

Pain Relief and and Peripheral Perfusion Index During Erector Spinae Block

An interventional study of Erector Spinae Plane Block in Block, Block, Fascicular and Spinae, sponsored by Keimyung University Dongsan Medical Center. Completed at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Keimyung University Dongsan Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The primary endpoint of this study is to compare the pain relief and peripheral perfusion index when local anesthetics injected in different final target area during lumbar erector spinae block The secondary endpoint of this study is to compare the procedure related pain

Read the detailed description

The erector spinae plane block (ESPB) is a less invasive, safer, and technically easy alternative procedure to conventional neuraxial anesthetic techniques. In contrast to common neuraxial techniques such as paravertebral and epidural injections, the ESPB targets an interfascial plane which is far from the spinal cord, root, and pleura. First applied to thoracic neuropathic pain, currently ESPB is being applied to postoperative pain control and includes variable clinical situations. In the abdomen and thoracic wall, thoracic ESPB can be applied for pain control after cardiac surgery, video-assisted thoracic surgery, laparoscopic cholecystectomy, and thoracotomy. Recently, favorable postoperative pain control after lumbar spinal or lower limb surgeries has been reported with lumbar ESPB. In addition, ESPB has also been used for chronic pain conditions in the upper and lower extremities. The final target area of ESPB of cervical, thoarcic, and lumbar regiona is transverse process. Once the needle contact the tip of the transverse process, local anesthetics is injected subsequentely. However, contacting the bony structure with the needle can generage procedure related pain. If ESPB can be performed without touching the transverse process, the satisfaction of patient would be increased. Actually, intertransverse ligament, which is visibe by ultrasound, is present between transverse process. Therefore, if local anesthetics is injected after targeting intertransverse ligament, same effect of pain relief with tarting of transverse process of ESPB is uncertain

02

Conditions studied

  • Block
  • Block, Fascicular
  • Spinae

Browse trials for

03

In context

Bundle-Branch Block

94 studies on the registry are indexed under Bundle-Branch Block; 30 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 59 interventional studies indexed under Bundle-Branch Block.

Browse Bundle-Branch Block studies →

Lead sponsor

Keimyung University Dongsan Medical Center is the lead sponsor of 86 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • lumbar disc herniation
  • lumbar foraminal stenosis
  • lumbar central stenosis
  • lumbar spondylolisthesis
  • numerical rating scale > 4
  • back pain functional scale \< 45
  • duration of pain > 1 mon
  • patients who can fully understand all items described in back pain functional scale

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics or contrast medium
  • Pregnancy
  • Spine deformity
  • Prior history of lumbar spine surgery
  • No previous lumbar MRI or CT
  • Patients with coagulation abnormality
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    intertransverse ligagment group

    lumbar ESPB was performed with final target at intertransverse ligament

    Procedure: Erector Spinae Plane Block

  • Placebo comparator
    transverse process group

    lumbar ESPB was performed with final target at transverse process

    Procedure: Erector Spinae Plane Block

Interventions

  • ProcedureErector Spinae Plane Block

    lumbar erectro spinae block

06

What researchers measure

Primary outcomes

  1. Numerical rating scale changes among 5 times period

    minimum (1) and maximum value (10), lower score means better treatment outcome

    Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks after the completion of erector spine plane block

Secondary outcomes

  1. back pain functional scale among 3 times period

    minimum (0) and maximum value (60), higher score means better treatment outcome

    Time frame: Baseline, 4 weeks, 8 weeks after the completion of erector spine plane block

07

Study locations

1 site
  • Hong Ji Hee
    Daegu, Daegu 42178, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Dec 2025, 7 months.

Of 32 interventional studies with no phase under Bundle-Branch Block, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 9, 2025
StartActual
May 13, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06963424
Lead sponsor
Keimyung University Dongsan Medical Center
Responsible party
Ji Hee Hong (Professor, Keimyung University Dongsan Medical Center) — Principal investigator
First posted
May 9, 2025
Start date
May 13, 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Jan 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion